Researcher:
Ulukan, Bürge

Profile Picture
ORCID

Job Title

PhD Student

First Name

Bürge

Last Name

Ulukan

Name

Name Variants

Ulukan, Bürge

Email Address

Birth Date

Filters

2019 - 201922020 - 20221

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.344e63c9-6008-43e9-b359-42be35c90780

Search Results

Now showing 1 - 3 of 3
  • Placeholder
    PublicationMetadata only
    DNA methylation pattern of TM6SF2 influences NAFLD progression in genotype-dependent manner
    (Elsevier, 2019) Adalı, Gupse; Dayangaç, Murat; N/A; N/A; N/A; N/A; N/A; N/A; Ulukan, Bürge; Yiğit Alpdoğan, Buket; Yılmaz, Onur; Cömert, Melis Cansu; Erkan, Murat Mert; Zeybel, Müjdat; PhD Student; Researcher; Undergraduate Student; Undergraduate Student; Faculty Member; Faculty Member; Graduate School of Health Sciences; N/A; School of Medicine; School of Medicine; School of Medicine; School of Medicine; N/A; N/A; N/A; N/A; 214689; 214694
    N/A
  • Placeholder
    PublicationMetadata only
    Advances in the epigenetics of fibroblast biology and fibrotic diseases
    (Elsevier Sci Ltd, 2019) Ulukan, Bürge; Özkaya, Yasemin Sıla; Zeybel, Müjdat; PhD Student; Undergraduate Student; Faculty Member; Graduate School of Health Sciences; School of Medicine; School of Medicine; N/A; N/A; 214694
    Fibroblasts have a central role in tissue fibrosis and fibrotic diseases. Fibroblast activation is regulated by several mechanisms including epigenetic modifications; histone modifications, DNA methylation and non-coding RNAs. Although research has significantly contributed to our basic understanding of fibrotic diseases over the last decade, cooperative activity of epigenetic mechanisms demonstrates the complexity of fibrogenesis. This review will summarise the latest epigenetic advances in fibroproliferative diseases. Current studies investigating biological implications of epigenetic modifiers, inhibitors of DNA methylation/histone modifying enzymes are promising. Given that ncRNA-based or CRISPR-based epigenetic-editing have shown therapeutic potential in the preclinical models; we consider epigenetic mechanisms represent a potential tool with clinical utility.
  • Thumbnail Image
    PublicationOpen Access
    Multiomics analysis reveals the impact of microbiota on host metabolism in hepatic steatosis
    (Wiley, 2022) Arif, Muhammad; Li, Xiangyu; Altay, Özlem; Shi, Mengnan; Shoaie, Saeed; Türkez, Hasan; Nielsen, Jens; Zhang, Cheng; Uhlen, Mathias; Boren, Jan; Mardinoğlu, Adil; Yang, Hong; Ural, Dilek; Akyıldız, Murat; Gönenli, Mehmet Gökhan; Kurtoğlu, Burçin Sağlam; Yiğit Alpdoğan, Buket; Ulukan, Bürge; Zeybel, Müjdat; Faculty Member; Faculty Member; Teaching Faculty; Faculty Member; Graduate School of Health Sciences; School of Medicine; 1057; 123080; 350445; N/A; N/A; N/A; N/A
    Metabolic dysfunction-associated fatty liver disease (MAFLD) is a complex disease involving alterations in multiple biological processes regulated by the interactions between obesity, genetic background, and environmental factors including the microbiome. To decipher hepatic steatosis (HS) pathogenesis by excluding critical confounding factors including genetic variants and diabetes, 56 heterogenous MAFLD patients are characterized by generating multiomics data including oral and gut metagenomics as well as plasma metabolomics and inflammatory proteomics data. The dysbiosis in the oral and gut microbiome is explored and the host-microbiome interactions based on global metabolic and inflammatory processes are revealed. These multiomics data are integrated using the biological network and HS's key features are identified using multiomics data. HS is finally predicted using these key features and findings are validated in a follow-up cohort, where 22 subjects with varying degree of HS are characterized.